Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)
| CAPS Rating |
|
|---|---|
| Open | $41.86 |
| Previous Close | $42.45 |
| Daily Range | $41.41 - $42.20 |
| 52-Week Range | $27.17 - $46.07 |
| Market Cap | $2.65B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 785,462 |
| Average Daily Volume | 0 |
ONXX
VS S&P 500 (SPY)
How do you think ONXX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ONXX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ONXX News and Commentary
- Kidney Cancer? There's a Drug for That – The Motley Fool
- FDA Approval Isn't Enough – The Motley Fool
- 3 Biotech Buyout Candidates for 2012 – The Motley Fool
- UPDATE: FDA Approves Pfizer's Inlyta For Advanced Kidney Cancer – SmartMoney
- The Fastest-Growing Biotech Stocks – The Motley Fool
- 2 Medical Stocks to Buy, 3 to Avoid in 2012 – Blogs @ The Motley Fool
- 2 High-Flying Biotechs Face a New Hurdle – The Motley Fool
- Bayer/Onyx Announce Cancer Data - Analyst Blog – NASDAQ
- High Expectations Trump Solid Results – The Motley Fool
- Aveo Pharmaceuticals Shares Plunged: What You Need to Know – The Motley Fool
- Cancer Drug Developer Aveo Shares Sink as Study Data Falls Short of Investor Hopes – Minyanville
- What to Look For From Keryx and Aeterna Zentaris in 2012 – The Motley Fool
- 2 Positive Signs for Ariad Pharmaceuticals – The Motley Fool
- Pipeline Setback at Bristol-Myers - Analyst Blog – NASDAQ
- Bristol-Myers Drug Misses Survival Goal In Liver Cancer Trial – SmartMoney
- ARIAD's Prolific 2011 – The Motley Fool
- Cell Therapeutics' Wild Week – The Motley Fool
- Standard FDA Review for Onyx Drug - Analyst Blog – NASDAQ
- FDA Irony: Less Data, Longer Review – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
RSS Headlines
Fool UK
